Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

Trident Lifeline Limited

Healthcare › Pharmaceuticals & Biotechnology
₹382.00
at close · 22 Sept 2026
▲ 12.05 (+3.26%)

Latest filings

  1. Trident Lifeline to attend Arihant Capital Bharat Connect conference on Sep 25 · Board & Shareholder Meetings
  2. Trident Lifeline honoured by PHARMEXCIL for pharma exports · Business Updates
  3. Trident Lifeline publishes 13th AGM notice and e-voting details in newspapers · Compliance
  4. Trident Lifeline FY26 Annual Report: Revenue 129cr, PAT up 84% · Results
  5. Trident Lifeline 13th AGM on September 26, 2026 via video conferencing · Board & Shareholder Meetings
  6. Trident Lifeline revises Book Closure dates for 13th AGM · Corporate Actions
  7. Newspaper ad published for 13th AGM on September 26, 2026 via video conferencing · Compliance
  8. Trident Lifeline allots 24000 shares on warrant conversion · Fund Raising
  9. Trident Lifeline allots 24000 shares on warrant conversion · Fund Raising
  10. Trident Lifeline selected for Pharmexcil pharmaceutical exports award · Business Updates
  11. Board approves AGM notice, director reappointment; books to close Sep 19-26 · Board & Shareholder Meetings
  12. Board approves FY26 report, sets 13th AGM for Sept 26 via VC · Board & Shareholder Meetings
  13. Trident Lifeline featured in India Pharma Outlook Magazine · Business Updates
  14. Trident Lifeline wins Fastest Growing SMEs award at Gujarat Top 50 SME Awards · Business Updates
  15. Analyst/Institutional Investor Meeting Outcome - August 20, 2026 · Investor Communications
  16. Trident Lifeline holds one-on-one investor meetings on 20 Aug 2026 · Board & Shareholder Meetings
  17. Trident Lifeline wins Fastest Growing SME award in Gujarat · Business Updates
  18. Trident Lifeline Q1 FY27 earnings: revenue up 43 percent, PAT up 82 percent YoY · Investor Communications
  19. Earnings Presentation Q1 FY27, revenue up 43 percent, PAT up 82 percent · Investor Communications
  20. Q1 FY27 unaudited results published in newspapers · Compliance
  21. Trident Lifeline Q1 FY27: Revenue up about 43% YoY, PAT rises about 64% · Results
  22. Trident Lifeline Q1 FY27 results: revenue up 43%, PAT up 89% YoY · Results
  23. Board meeting on July 29 to consider Q1 FY27 unaudited results · Results
  24. Postal Ballot Results: 3 Resolutions Passed Including BSE-NSE Main Board Migration · Board & Shareholder Meetings
  25. 3 Resolutions Pass in Postal Ballot - 2 Directors Appointed, Move to BSE and NSE Main Boards Approved · Board & Shareholder Meetings
  26. RTA confirms processing of demat requests for Q1 FY26 · Compliance
  27. Trading window closed from July 1 for Q1 results · Compliance
  28. Subsidiary TML private placement; parent stake dips to 58.67% · Fund Raising
  29. Promoter Trust buys 1,200 shares of Trident Lifeline via open market · Ownership Changes
  30. Trident Lifeline issues postal ballot notice to shareholders · Board & Shareholder Meetings
  31. Newspaper Advertisement of Postal Ballot Notice Published · Compliance
  32. We wish to inform to the Exchange that TRIDENT MEDIQUIP LIMITED (TML) (CIN: U33309GJ2019PLC110421), a subsidiary company has made Private Placement of equity shares to other shareholders. .... · Fund Raising
  33. The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shikha Bafna · Ownership Changes
  34. The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Hardik Desai Family Trust<BR> · Ownership Changes
  35. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Earnings Presentation for the half year and year ended .... · Investor Communications
  36. In accordance with Regulation 47 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, we hereby enclose copies of newspaper advertisement .... · Compliance
  37. The Board of Directors has inter alia approved the Appointment of DAC & Co. Chartered Accountants, (FRN: 137035W, PR: 014160) as Internal Auditor of the Company for Financial Year 2026-2027 · Results
  38. Audited Financial Result (Standalone and Consolidated) for the Half year and year ended 31.03.2026 · Results
  39. The Board of Director of the Company has approved the Audited Financial Result (Standalone and Consolidated) for the Half year and Year eneded on 31.03.2026 · Results
  40. The Board Meeting to be held on 05/05/2026 has been revised to 07/05/2026 The Board Meeting to be held on 05/05/2026 has been revised to 07/05/2026 · Board & Shareholder Meetings
  41. <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> .... · Compliance
  42. Trident Lifeline Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2026 ,inter alia, to consider and approve Audited Financial Results .... · Results
  43. Subsidiary Trident Mediquip makes private placement of equity shares · Fund Raising
  44. We wish to inform to the Exchange that TRIDENT MEDIQUIP LIMITED (TML) (CIN: U33309GJ2019PLC110421), a subsidiary company has made Private Placement of equity shares to other shareholders. .... · Fund Raising
  45. Please find enclosed herewith the Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 as received from MUFG Intime India Private Limited (Formally .... · Compliance
  46. Promoter group member Amit Halvawala sells 34,800 shares in open market · Ownership Changes
  47. The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rinkal Mayurbhai Gajera · Ownership Changes
  48. The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Hardik Desai Family Trust · Ownership Changes
  49. The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rupaben Jariwala · Ownership Changes
  50. Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, we wish to inform you that the Trading Window for dealing in securities of the Company shall remain closed with effect .... · Compliance
All filings ↓
Ask Nexa about Trident Lifeline Limited

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Sells a wide pharmaceutical product portfolio of 3,625 products, with 1,091 products registered across 46 countries and 2,534 registrations pending, generating revenue from both domestic and export markets. In FY26, consolidated revenue was Rs 129.02 crore, up 48.4% year-on-year, driven by growth in pharmaceutical sales. The company also operates a medical-device subsidiary, Trident Mediquip Limited (TML), in which it holds around 58.67% and which reported turnover of Rs 27.31 crore in FY26 versus Rs 21.29 crore in FY25. Materials are the single largest cost at 46.5% of revenue, followed by other operating expenses at 10.6% and employee costs at 8.4%. Capital expenditure absorbed 28.3% of revenue in FY26, reflecting ongoing investment in the business. The company is currently migrating its listing from the BSE SME platform to the BSE and NSE main boards.

Operating scale
Product portfolio
3,625 productsFY26
Products registered across markets
1,091 products in 46 countriesFY26
Pending registrations
2,534 registrations in pipelineFY26
Subsidiary turnover (Trident Mediquip)
Rs 27.31 croreFY26
Capex intensity
28.3% of revenueFY26
Listing migration
From BSE SME to BSE & NSE main boardsFY27
Who pays it
Pharmaceutical buyers in domestic and 46 international markets, plus medical-device customers via subsidiary
Biggest cost
Materials and inputs at 46.5% of revenue
Kind of business
Pharmaceutical formulations exporter with a growing medical-device subsidiary and heavy reinvestment
Where it sits
Small-cap pharmaceutical company with a broad 3,625-product portfolio and registrations spanning 46 countries, migrating from BSE SME to main-board listing
Market Cap
₹456 Cr
P / E (TTM)
15.7×
EV / EBITDA
—
Div Yield
—
Growth
—·
Revenue 5y CAGR
PAT — · EBITDA —
Quality
21.0%▲
ROCE (5y median)
ROE — · margin —
Leverage
—·
Debt / Equity
Net debt ₹-4 Cr
Revenue FY23→FY26
4.1×▲
Revenue change
₹32 Cr → ₹129 Cr
Moves on a normal day
1.32%·
Median daily move
Last 251 sessions · filing days run larger
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#42/170
ROCE#43/183
Revenue growth#25/161

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Returns on capital 21.0%
#43 of 183 in Pharmaceuticals on the latest reported figures · up from 14.7% in FY23
Concerns
Nothing flagged in the filed numbers.

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from Trident Lifeline Limited's filed financials and exchange disclosures

What does Trident Lifeline Limited do?

Trident Lifeline Limited is a Pharmaceuticals & Biotechnology company listed on BSE.

Is Trident Lifeline Limited debt-free?

Effectively yes. It holds ₹4 Cr more cash than debt.

Is Trident Lifeline Limited expensive compared with its peers?

On trailing P/E, Trident Lifeline Limited ranks 42 of 170 in Pharmaceuticals — cheaper than 76% of them, against an industry median of 29.6×. This is a position, not a valuation judgement.

How much does the Trident Lifeline Limited share price move in a day?

On a typical session Trident Lifeline Limited moves 1.32% — that is the median absolute close-to-close move across its last 251 trading days. Announcement days are routinely larger.

Where can I track Trident Lifeline Limited's announcements?

Every NSE and BSE filing by Trident Lifeline Limited appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.